Latest news with #FlemmingOrnskov
Yahoo
a day ago
- Business
- Yahoo
Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership
Strategic move aims to accelerate innovation and growth in the U.S., Galderma's largest region MIAMI, June 17, 2025 /PRNewswire/ -- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the establishment of its new U.S. headquarters in Miami, Florida, positioning the company at the heart of a thriving market for Dermatological Skincare and Injectable Aesthetics. Located in the vibrant Brickell neighborhood, the company expects to have approximately 150 employees, including U.S. leadership roles, based there by 2028. Miami's emergence as a premium market and destination for consumer skincare, consumer health, and aesthetic treatments aligns closely with Galderma's ambitions for its U.S. business, which is the company's largest region globally and a key driver of future growth. "Miami's creativity, energy and forward-thinking spirit are consistent with Galderma's ambitions. The city's emergence as a premium destination and a trend-setter in areas closely aligned to our activities, as well as its fast-growing healthcare professional community, makes Miami a natural choice for our U.S. headquarters. Being in Miami will enrich our business with top talent that will prove invaluable to our future success." FLEMMING ØRNSKOV, M.D., MPH CHIEF EXECUTIVE OFFICERGALDERMA The Miami metro area boasts one of the highest concentrations of medical spas and dermatological aesthetic clinics in the United States, with aesthetic procedures growing at an estimated 30% year-over-year. It also hosts the nation's second-largest medical district, the Miami Health District, with numerous hospitals and research facilities. With over 186,000 healthcare-related jobs and significant growth in startups, Florida is a hub for innovation in health and advanced medical technologies. Miami plays an important role in this ecosystem, with renowned research institutions and medical centers that house dedicated clinical teams focused on dermatology. "We are delighted to welcome Galderma to the Miami-Dade County area, which has witnessed considerable growth recently as companies increasingly find it to be an attractive location for investment. Miami-Dade has established itself as a key player in the life sciences and healthcare industry and having the pure-play dermatology industry leader anchor its U.S. business here will only bolster the region's reputation for innovation in this sector." RODRICK MILLERPRESIDENT AND CHIEF EXECUTIVE OFFICERMIAMI-DADE BEACON COUNCIL In addition to its new headquarters in Miami, Galderma will maintain a strong presence across several U.S. locations. Boston, MA, will remain the hub for the company's U.S. Therapeutic Dermatology business and U.S. Research and Development organization. Carlsbad, CA, will continue as a hub for Alastin®, the company's premium, physician-dispensed skincare brand. The Dallas, TX, office will continue as one of Galderma's key U.S. sites while the company's North America distribution center will remain in Fort Worth, TX. APPOINTING A NEW LEADER FOR GALDERMA has also announced today the appointment of Heather Wallace as President of Galderma U.S. Heather will be based in Miami. A proven senior business leader with deep expertise in dermatology and consumer health, she brings a strong track record of delivering commercial success and operational excellence. Heather previously led high-performing teams as Chief Executive Officer of Curology, the leader in personalized prescription skincare, and as President of the Americas region for Revlon, where she oversaw strategic and cultural transformation efforts to maximize profitability in the company's largest region. Her appointment signals Galderma's commitment to strengthening its U.S. leadership with forward-thinking talent capable of driving sustained growth in a dynamic and highly competitive landscape. GALDERMA'S LEADING PORTFOLIO OF PREMIUM BRANDSGalderma's synergistic portfolio of flagship brands holds leading market positions in Dermatological Skincare, Injectable Aesthetics, and Therapeutic Dermatology. In Dermatological Skincare, Galderma is best known for Cetaphil®, a leading dermatologist recommended brand for sensitive skin with more than 70-year heritage in the United States. Galderma's premium portfolio also includes the physician-dispensed skincare brand Alastin®, a leader in medical-grade peptide-based regenerative skincare. In Injectable Aesthetics, Galderma has a long history of aesthetics innovation and deep expertise in neuromodulators, as well as hyaluronic acid (HA) fillers and biostimulators. In Therapeutic Dermatology, Galderma brands hold leading positions in acne and rosacea and the company recently launched the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31 in prurigo nodularis and atopic dermatitis. ABOUT GALDERMAGalderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: For further information: Christian Marcoux, Chief Communications Officer +41 76 315 26 50 Jeffrey Smith Head of U.S. Communications +1 (682) 401-8428 Richard Harbinson Corporate Communications Director +41 76 210 60 62View original content to download multimedia: SOURCE Galderma
Reuters
24-04-2025
- Business
- Reuters
Skincare company Galderma keeps 2025 outlook, shrugs off U.S. tariff uncertainty
ZURICH, April 24 (Reuters) - Swiss skincare company Galderma (GALD.S), opens new tab on Thursday said its sales rose by 8.3% on the year to $1.13 billion during the first quarter and signalled confidence about its prospects for the rest of 2025 despite ongoing uncertainty over U.S. tariffs. Chief Executive Officer Flemming Ornskov told Reuters the company was sticking its outlook for 2025 as it rolls out new products and pursues increased market share, stressing that Galderma was "totally committed to the U.S." "The vast majority of our portfolio is not affected by these tariffs right now," Ornskov said, noting that only nine percent of the firm's total sales were impacted by import duties. "The way we want to manage this situation is to focus on commercial execution, volume, market share gain," he added. Galderma, which launched on the Swiss stock exchange in March 2024, saw its shares gaining 8.5% in early trading after the results. Bank Vontobel analyst Stefan Schneider said Galderma's results were positive. "Over-delivery of 1Q25 sales allows the company to increasingly de-risk and confirm its FY25 guidance despite some further tariff impact in some consumer product categories," he said.
Yahoo
07-03-2025
- Business
- Yahoo
Galderma to discuss U.S. tariffs with retailers, sees "moving target"
ZURICH (Reuters) - Swiss skincare company Galderma will talk to major American retailers about trade tariffs imposed by the U.S. government in order to manage their impact, CEO Flemming Ornskov said on Thursday. U.S. President Donald Trump this week slapped tariffs of 25% on Canada and Mexico, though his administration later said it would temporarily exempt automakers and consider other products. "We will be talking to Walmart, Target, Amazon, and others to figure out how we're going to react to this, also price-wise," Ornskov told Reuters after Galderma posted a 9.3% sales increase for 2024 and net income of $231 million. He described tariffs as "a bit of a moving target," noting that their scope could still be altered. Ornskov said his company had already taken "precautions on stock and other things" in the U.S. to mitigate the impact on Galderma, which has major production operations in Canada. "Another way of compensating this would be just to drive more volume with your product," he said. Galderma's net U.S. sales were flat in 2024 on the year and fell in the final quarter. Ornskov said there were specific factors behind that and was confident U.S. sales would grow in 2025. Trump has also threatened to impose tariffs on Europe. As most aesthetic companies produce in Europe, they and Galderma would be affected, Ornskov said. Galderma's results come almost a year after it listed on the Swiss stock exchange. Its share price has since doubled from its initial launch price, though the stock fell by as much as 9% on Thursday before paring losses. Sign in to access your portfolio
